Fortis Healthcare Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 10% at ₹1/Share	24-Jul-2026	24-Jul-2026
DividendsFinal Dividend of 10% at ₹1/Share	25-Jul-2025	25-Jul-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
HDFC Mid Cap Fund - Regular Plan - Growth	3.21 Cr	3.17 Cr (1.25%)
Kotak Mid Cap Fund - Regular Plan - Growth	2.81 Cr	3.02 Cr (7.34%)
Nippon India Growth Mid Cap Fund - Growth Option	1.50 Cr	1.65 Cr (9.69%)
Axis Midcap Fund - Regular Plan - Growth	1.25 Cr	1.14 Cr (9.16%)
DSP Midcap Fund - Regular Plan - Growth	64.68 Lac	63.95 Lac (1.13%)

SASI KUMAR SEBI RA

20 Oct • 1:10 PM · SEBI-Registered Analyst

Healthcare Stocks for a Long-Term Watchlist

Healthcare demand does not depend entirely on how the stock market performs. People need medical treatment in good and bad economic conditions. Rising incomes, wider insurance coverage and higher spending on healthcare can support the sector over time. Here are 7 listed healthcare companies to study for a long-term watchlist: • Apollo Hospitals • Max Healthcare • Fortis Healthcare • Narayana Health • KIMS • Rainbow Children’s Medicare • Aster DM Healthcare Before investing, compare each company’s valuation, revenue growth, debt, margins and expansion plans. A growing sector does not mean every stock is available at the right price. Not a buy/sell recommendation. For educational purposes only.

Vibhu Jain

19 Oct • 4:12 PM · SEBI-Registered Analyst

Fortis Healthcare analysis on different parameteres

FORTIS

Quality :- Fortis Healthcare Ltd’s quality assessment remains favourable, indicating a stable operational foundation. The company’s debt-equity ratio, reported at 0.35 times for the half-year ended June 2026, is among the highest in recent periods, signalling a cautious approach to leverage. Despite this, the company’s core business fundamentals continue to demonstrate resilience, with flat financial results reported in the latest half-year. This stability in earnings suggests that while growth momentum may be subdued, the underlying business quality has not deteriorated significantly. Valuation :- The valuation perspective on Fortis Healthcare Ltd is characterised as fair, reflecting a balance between the company’s market price and its intrinsic worth based on current financial data. The stock’s market capitalisation places it in the midcap category within the hospital sector, where valuation multiples often reflect sector-specific risks and growth prospects. The recent market performance, however, has been underwhelming, with the stock’s price retreating more sharply than broader indices, which may have influenced the revision in valuation assessment. Technical :- a technical standpoint, the stock exhibits a bearish trend. Price movements over various time frames reveal a consistent downward trajectory. The stock’s returns over the past month and quarter have been notably negative, with declines of 15.59% and 22.42% respectively. Even over the one-year horizon, the stock has underperformed the broader market significantly, with a return of approximately -31.94% compared to the BSE500’s negative return of -6.02%. This persistent underperformance has likely influenced the revision in the stock’s technical assessment, signalling caution among market participants.

DEEPAK PAL

14 Oct • 11:55 AM · SEBI-Registered Analyst

SECTOR CORNER---> KNOW WHICH SECTORS ARE IN NEWS & EVENTS !

Healthcare Faces Regulatory Pressure; EV Theme Puts Auto Stocks in Focus Two sectors are attracting investors’ attention today: Healthcare, amid Supreme Court scrutiny of medicine pricing, and Automobiles, as Nomura highlights opportunities linked to rising EV adoption. IT stocks are also in focus following the recent earnings-led rally. 1. HEALTHCARE & HOSPITALS: REGULATORY UNCERTAINTY RISES Morgan Stanley’s View on Indian Healthcare The Supreme Court has questioned why medicine price controls are limited to cancer drugs and why manufacturers can set prices for several other medicines and medical products. --->Stocks to Watch

APOLLOHOSP

Max Healthcare Fortis Healthcare Aster DM Healthcare Dr. Lal PathLabs Market impact: Hospital stocks may remain sensitive to developments around medicine pricing, particularly if investors expect tighter controls on pharmacy-related margins. Pharmaceutical companies could also face uncertainty if price regulation expands beyond oncology. 2. AUTOMOBILES & EVs: NOMURA FAVOURS EV-EXPOSED COMPANIES Nomura’s Preferred Auto Picks Nomura believes companies with competitive electric-vehicle products, established technology and greater EV exposure could outperform the broader automobile industry in the second half of FY27 and FY28. --->Stock View Ather Energy BUY Mahindra & Mahindra BUY Hyundai Motor India BUY Tata Motors Passenger Vehicles NEUTRAL Sona BLW Precision Forgings BUY Exide Industries BUY 3. INFORMATION TECHNOLOGY: EARNINGS-LED MOMENTUM CONTINUES Tata Elxsi also attracted attention after reporting a year-on-year increase in September-quarter profit. However, Morgan Stanley and Motilal Oswal maintained cautious views on the stock, highlighting the importance of looking beyond the immediate earnings reaction. Stocks to Watch HCLTech Tata Elxsi Tech Mahindra TCS Wipro

Pavan Rawat

12 Oct • 6:15 PM · SEBI-Registered Analyst

APOLLO HOSPITALS, FORTIS; CANCER DRUG CAP MAY HIT EBITDA

APOLLOHOSP

Experts maintained its ‘Neutral’ ratings on Apollo Hospitals and Fortis, estimating that the government’s decision to cap trade margins on non-scheduled anti-cancer drugs at 30% could have a mid-to-high single-digit impact on the EBITDA of its covered hospitals. Given that a significant proportion of oncology drugs are dispensed through hospital channels, hospitals are expected to bear the greatest direct impact, followed by wholesalers, while retailers are likely to experience minimal effects. On October 8, the government approved a 30% cap on trade margins for non-scheduled anti-cancer drugs, calculated as a percentage of the maximum retail price (MRP). The move is expected to reduce medicine prices by up to 70% and deliver annual savings of approximately Rs 25 billion to patients. The regulation covers around 110 anti-cancer drugs, including 35 patented medicines, and applies to branded and generic formulations, as well as domestic and imported products, irrespective of patent status. Apollo Hospitals experienced revenue and EBITDA compression of approximately Rs 100 million per quarter in FY18 following the cap on stent prices. However, the impact was fully recovered by the end of FY19. Apollo’s EBITDA margin declined to 11.6% in FY18 from 12.0% in FY17, but the company subsequently mitigated the pressure through service price increases and higher bundled pricing.

Finkhoz Roboadvisory Services

1 Oct • 4:59 PM · SEBI-Registered Analyst

Apollo Hospitals extends fall as drug mark-up concerns

APOLLOHOSP

Enterprise Limited (APOLLOHOSP) fell 2.3% to ₹7,978 in early trade on October 1, extending losses for a second session. The stock was among the top Nifty 50 losers, a day after closing 6.6% lower on Supreme Court remarks about medicine mark-ups at private hospitals. The court cited a cancer drug with an MRP of ₹27,000 despite a price to retailers of ₹2,700. It questioned whether a uniform 16% margin could apply to medicines, and raised concerns about hospitals making patients buy through in-house pharmacies. The selling was sector-wide. Max Healthcare, Fortis Healthcare and KIMS were also down over 2% today. The concern is real, but its size is still unclear. Jefferies estimates medicines and consumables make up around 15-20% of hospital revenue. It puts the potential EBITDA impact at 2-5% under various price-cap scenarios, assuming hospitals cannot pass it on. The brokerage kept its positive view on the sector. HSBC also flagged pricing intervention as a key concern, while noting the ground-level impact remains uncertain. Most importantly, this is not yet a rule. The court's observations have not turned into a binding price-control order. The two-day fall reflects the market pricing in regulatory risk before any policy exists. Investors should watch for any government or regulatory action on hospital medicine pricing, the next court hearing, and management commentary in Q2 FY27 results. The key question is whether this ends as court observations or becomes a formal margin cap on hospital pharmacies. Disclosure: I do not hold any position in Apollo Hospitals Enterprise Limited. This post is for informational purposes only and is not investment advice.

Kavan Patel

1 Oct • 3:32 PM · SEBI-Registered Analyst

Sensex, Bankex analysis for 01/10/2026(MARKET ANALYSIS)

1. Sensex Technical Overview Current Level: 72,480 Key Trend / Positioning: Hold Short (below 74,000): The current price of 72,480 sits comfortably below the major psychological and technical resistance threshold of 74,000. As long as Sensex trades below this boundary, the prevailing momentum favors downside continuation or a weak range-bound structure, supporting short positions. Conditional Long (above 74,000): A decisive breakout and sustained move above 74,000 would invalidate the short thesis, signaling a shift in market structure and a bullish trend reversal. Traders are advised to switch strategies to create long positions only upon confirmation of this breakout. 2. Bankex Technical Overview Current Level: 61,725 Key Trend / Positioning:Hold Short (below 63,000): Trading at 61,725, Bankex exhibits weakness as it remains capped under the key resistance barrier of 63,000. Holding short positions is favored in this zone, reflecting ongoing selling pressure or corrective momentum in banking constituents. Conditional Long (above 63,000): A reclaim of the 63,000 level would indicate aggressive institutional buying and a break of immediate overhead resistance. Long setups should only be initiated conditionally once the index successfully breaks and holds above this threshold. F&O top looser was :

FORTIS

Fortis Healthcare Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Fortis Healthcare Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Fortis Healthcare Ltd.?

What is the market cap of Fortis Healthcare Ltd.?

Should I buy Fortis Healthcare Ltd. stock now?

What is the 52 week high and low of Fortis Healthcare Ltd.?

Is the Fortis Healthcare Ltd. stock good to buy?

Is Fortis Healthcare Ltd. a good buy for the long term?

Is Fortis Healthcare Ltd. overvalued or undervalued?

What is the PE and PB ratio of Fortis Healthcare Ltd.?